
Millions of children at risk as global vaccine rates fall, study finds
Millions of children worldwide are at risk of lethal diseases because vaccine coverage has stalled or reversed amid persistent health inequalities and soaring levels of misinformation and hesitancy, the largest study of its kind has found.
Major progress in rolling out jabs to billions of children in all corners of the globe over the last five decades has prevented the deaths of 154 million children, according to an analysis published in the Lancet.
But since 2010, progress has stalled or reversed in many countries. Measles vaccination rates have fallen in 100 of 204 countries, while coverage for at least one dose against diphtheria, tetanus, whooping cough, measles, polio or tuberculosis has declined in 21 of 36 high-income countries – including France, Italy, Japan, the UK and the US.
The reversal, further exacerbated by the disruption caused by the Covid-19 pandemic, has left millions of children vulnerable to preventable diseases and death, the authors of the study led by the University of Washington in Seattle said.
'Despite the monumental efforts of the past 50 years, progress has been far from universal,' said senior study author Dr Jonathan Mosser from the Institute for Health Metrics and Evaluation at the University of Washington. 'Large numbers of children remain under- and un-vaccinated.
'Routine childhood vaccinations are among the most powerful and cost-effective public health interventions available, but persistent global inequalities, challenges from the Covid pandemic, and the growth of vaccine misinformation and hesitancy have all contributed to faltering immunisation progress.
'These trends increase the risk of outbreaks of vaccine-preventable diseases, including measles, polio and diphtheria, underscoring the critical need for targeted improvements to ensure that all children can benefit from lifesaving immunisations.'
The findings should be taken as a clear warning that global immunisation targets for 2030 will not be met without urgent action to turn things around, researchers said.
Vaccine-preventable disease outbreaks pose a growing global risk. Increasing numbers of wild-type polio cases have been reported in Afghanistan and Pakistan, and there is a polio outbreak in Papua New Guinea, where less than half of the population is immunised.
In 2024, there was a nearly tenfold increase in measles infections recorded in Europe. The measles outbreak in the US reached more than 1,000 confirmed cases in 30 states in May 2025, surpassing the total number of cases in 2024.
The new analysis provides updated and extended global, regional and national estimates of annual routine childhood vaccination coverage from 1980 to 2023 in 204 countries and territories, using more than 1,000 data sources.
The past 50 years has seen huge progress, the study shows, with a 75% drop in the number of unvaccinated zero-dose children worldwide from 58.8 million in 1980 to 14.7 million in 2019.
However, this long-term progress masks recent challenges and substantial disparities. Since 2010, coverage gains slowed and, in some areas of the world, reversed.
For example, 21 of 36 high-income countries experienced declines in coverage for at least one of the recommended vaccines – including a 12% decline in first-dose measles vaccination in Argentina, and 8% and 6% declines in third-dose diphtheria-tetanus-pertussis (whooping cough) vaccination in Finland and Austria respectively.
Persistent health inequalities and the enduring effects of the Covid-19 pandemic are key factors, but vaccine misinformation and hesitancy is the biggest new factor behind the stalling of progress.
Lead author Dr Emily Haeuser, of the University of Washington, called for more concerted efforts to tackle vaccine misinformation and hesitancy.
'Successful vaccination programmes are built on understanding and responding to people's beliefs, concerns and expectations,' she said.
Helen Bedford, professor of children's health at University College London, who was not involved with the study, said the reasons for declining vaccine uptake were 'numerous and complex'.
Action was necessary to tackle increasing social inequity, and misinformation about vaccine safety and necessity, as well as improving public confidence in vaccination programmes, she said.
'Vaccination remains one of our most powerful tools for protecting child health, but its continued success depends on sustained investment, equity, and public trust.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
4 minutes ago
- BBC News
New service launches to help young people on Guernsey quit vapes
A service to help young people in Guernsey to stop vaping has promised to support those "struggling to quit" by will run for an initial pilot period of six months and was available to young people aged 12-18. Set up by Public Health Services, in collaboration with Action for Children, care leavers will be able to use the service up to the age of sessions and nicotine replacement therapy will be provided for those heavily addicted. 'Team effort' Aaron Davies, Service Manager at Action for Children, said it was intended to "provide specific support to those struggling to quit on their own".Coinciding with regulation implemented at the start of this month banning the sale of vapes to under 18s, QuitVape aims to help young people reduce their use due to potential health risks that come with would be available in three tiers, including a self-help booklet available both online and at schools and community spaces, along with six face-to-face sessions offering vape tapering advice and extended behavioural provided are personal sessions provided by the School Nursing team for those more heavily offer immediate vaping cessation and nicotine replacement Hawkins-Drew, Associate Director of Public Health, called the pilot "a real team effort", while Katie Hill, School Nurse Team Leader, said it was "fantastic news" for those trying to cut down or quit.


BBC News
14 minutes ago
- BBC News
Lateral flow test could save people from deadly fungal infection
A new test which creators say could one day save the lives of people suffering from a deadly fungal infection is being developed at the University of commonly known as black fungus disease, spiked during the second wave of the Covid-19 pandemic. Now, Professor Chris Thornton, a professor in fungal immunology at the university, has developed a prototype lateral flow test, which could save valuable time in getting patients the treatment they test has been validated using patient samples could be ready to use in hospitals within three years if it passes regulatory checks, project leaders said. The fugal spores that cause black fungus disease are ever-present in the environment and harmless for most people. The disease is rare and thought to only affect those with compromised immunity. However, a combination of Covid infection, poorly-managed diabetes and an over-use of steroids to control lung inflammation from Covid led to a spike in infections. In 2021, there was an epidemic in India, with 40,000 cases leading to 3,500 deaths. Many of the survivors were left with facial still at prototype stage, a new study published in the Journal of Clinical Microbiology has shown the new test to be swift and accurate in identifying the disease. Professor Thornton, co-author of the study, said: "Mucormycosis is an horrific disease, which spreads rapidly in the body and can leave people horribly facially disfigured, and is often fatal.""Early diagnosis is crucial for the best outcome. This study shows that our new test is quick and effective. "These exciting results are a critical milestone in the development and validation of the test, which we aim to commercialise in the next three years." The study was conducted in partnership with colleagues at Besançon University hospital in France. Researchers tested the device in patients with mucormycosis, patients with other fungal infections, and patients without fungal infections. The test detects mucormycosis in 30 minutes with a high level of specificity and sensitivity.


The Independent
5 hours ago
- The Independent
Mother's delight as gene therapy offers hope to three-year-old
A child with a life-threatening disease has become the youngest in the UK to receive a groundbreaking gene therapy. Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development. Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate. But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising. It is hoped that she will make further strides as she ages. Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition. She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children. Sandeep Kaur said Gunreet has made 'great progress' since her treatment. 'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said. 'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held. 'Since having the gene therapy, Gunreet has made great progress. 'She cries less, smiles more, and can reach for objects. 'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see. 'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.' AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement. People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain. This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children. The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood. The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene. The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition. It is the first NHS England commissioned gene therapy in the UK infused directly into the brain. Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families. 'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult. 'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics. 'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies. 'It's great to see how this treatment has been able to help babies and children across the country like Gunreet. 'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone. 'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises. 'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.' Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives. 'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'